LAUSR

We commend the authors for their open-label clinical trial demonstrating the benefit of combination of lauromacrogol sclerotherapy and dual-wavelength vascular laser in separate visits for the treatment of infantile hemangiomas (IHs). Although oral and topical beta-blockers or oral steroids are the most commonly used treatments, some patients may be unable to tolerate or their parents unwilling to assume the systemic risks of these medications, making sclerosing agents and lasers particularly attractive, localized treatment options. Sclerosing agents may also serve as a valuable adjunct therapy to decrease the total duration of concomitant systemic therapy; enhance efficacy for large, pedunculated, or rapidly proliferating lesions that aremore likely to be resistant to systemic therapies alone; or to reduce lesion bulk and reduce the risk of intraoperative bleeding before surgical excision.